The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM).
Marta Penas-Prado
No relevant relationships to disclose
Morris D. Groves
Honoraria - Merck
Research Funding - Merck
Aaron G. Mammoser
No relevant relationships to disclose
Isaac Melguizo
No relevant relationships to disclose
John Frederick De Groot
Consultant or Advisory Role - Genentech; VBL Therapeutics
Honoraria - Merck
Research Funding - AstraZeneca; EMD Serono; Sanofi
Charles A. Conrad
No relevant relationships to disclose
Ivo Tremont-Lukats
No relevant relationships to disclose
Monica Elena Loghin
No relevant relationships to disclose
Vinay K. Puduvalli
Consultant or Advisory Role - Genentech; Novartis
Honoraria - Genentech; Novartis
Research Funding - Celgene; Genentech; Merck; Pfizer
Erik P. Sulman
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Merck
Kenneth R. Hess
No relevant relationships to disclose
Kenneth D. Aldape
No relevant relationships to disclose
Mark R. Gilbert
Consultant or Advisory Role - EMD Serono; Genentech; Merck; Novartis
Honoraria - EMD Serono; Genentech; Merck; Novartis
Research Funding - Genentech; GlaxoSmithKline; Merck
W. K. Alfred Yung
Consultant or Advisory Role - Actelion; Merck; Novartis
Honoraria - Merck; Novartis
Research Funding - Daiichi Sankyo